- Home
- CDIO vs ALBT Comparison
CDIO vs ALBT Comparison
Compare CDIO & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDIO | ALBT |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CDIO | ALBT |
|---|---|---|
| Price | $2.98 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.4K | ★ 172.8K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,782.00 | ★ $1,611,940.00 |
| Revenue This Year | $1,434.82 | N/A |
| Revenue Next Year | $4,661.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.42 | $0.88 |
| 52 Week High | $39.30 | $11.66 |
Technical Indicators
Market Signals| Indicator | CDIO | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 48.73 | 41.98 |
| Support Level | $2.80 | $0.88 |
| Resistance Level | $3.26 | $1.77 |
| Average True Range (ATR) | 0.40 | 0.19 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.05 | 36.64 |
Price Performance
Historical ComparisonAbout CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.